Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 17, 2023

Efficacy and Safety of Avelumab Plus Axitinib vs Sunitinib by IMDC Risk Groups in Patients With Advanced RCC



Additional Info

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
ESMO Open 2023 Apr 25;8(3)101210, JBAG Haanen, J Larkin, TK Choueiri, L Albiges, BI Rini, MB Atkins, M Schmidinger, K Penkov, E Michelon, J Wang, M Mariani, A di Pietro, RJ Motzer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading